Geron (NASDAQ:GERN) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.02, Fidelity Earnings reports. Geron had a negative return on equity of 23.15% and a negative net margin of 3,232.73%.
Shares of Geron stock traded down $0.18 during midday trading on Friday, hitting $1.67. 4,474,863 shares of the company were exchanged, compared to its average volume of 6,412,801. The company has a market capitalization of $275.43 million, a PE ratio of -9.28 and a beta of 2.67. Geron has a 52 week low of $1.46 and a 52 week high of $6.99.
In related news, EVP Stephen Rosenfield sold 1,362,250 shares of the firm’s stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $4.51, for a total transaction of $6,143,747.50. Following the completion of the transaction, the executive vice president now owns 36,000 shares in the company, valued at approximately $162,360. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert J. Spiegel sold 175,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $6.85, for a total value of $1,198,750.00. Following the transaction, the director now owns 110,576 shares of the company’s stock, valued at approximately $757,445.60. The disclosure for this sale can be found here. 8.20% of the stock is owned by company insiders.
A number of analysts have commented on GERN shares. ValuEngine upgraded Geron from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. FBR & Co started coverage on Geron in a research report on Thursday, July 5th. They issued a “buy” rating for the company. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $5.75 to $1.50 in a research report on Tuesday, October 2nd. Zacks Investment Research downgraded Geron from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. Finally, BidaskClub downgraded Geron from a “sell” rating to a “strong sell” rating in a research report on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $3.76.
Geron Company Profile
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Featured Article: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.